Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
2013 |
| gptkbp:ATCCode |
N06AX26
|
| gptkbp:availableOn |
gptkb:tablet
|
| gptkbp:CASNumber |
508233-74-7
|
| gptkbp:chemicalFormula |
C18H22N2S
|
| gptkbp:contraindication |
hypersensitivity to vortioxetine
|
| gptkbp:drugClass |
antidepressant
serotonin modulator |
| gptkbp:eliminationHalfLife |
66 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:genericName |
gptkb:vortioxetine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Brintellix
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Takeda
gptkb:Lundbeck |
| gptkbp:mechanismOfAction |
serotonin reuptake inhibition
serotonin receptor modulation |
| gptkbp:metabolism |
liver (CYP2D6, CYP3A4, CYP2C9)
|
| gptkbp:otherName |
gptkb:Trintellix
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting constipation dizziness sexual dysfunction |
| gptkbp:usedFor |
gptkb:major_depressive_disorder
|
| gptkbp:bfsParent |
gptkb:Takeda_(Japan)
|
| gptkbp:bfsLayer |
6
|